You can buy or sell ACHV and other stocks, options, ETFs, and crypto commission-free!
Achieve Life Sciences, Inc. Common Shares, also called Achieve Life Sciences, is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Read More Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Vancouver, British Columbia
52 Week High
52 Week Low
Research And Development
Markets InsiderMar 18
Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
SEATTLE and VANCOUVER, British Columbia, March 18, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at Oppenheimer's 29th Annual Healthcare Conference in New York on Wednesday, March 20 at 2:10 p.m. Eastern Time. A live webcast of the presentation can be accessed at http...
Markets InsiderMar 14
Achieve Life Sciences Is All Fired Up - Stock Soars Over 70%
(RTTNews) - Shares of Achieve Life Sciences Inc. (ACHV) jumped over 70% in extended trading on Thursday as investors bet on the Company's Cytisinicline program, which is under development for smoking cessation. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfa...
PR NewswireMar 14
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, March 14, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results. Recent Highlights Completion of enrollment in 254-subject Phase 2b ORCA-1 trial of cytisinicline in U.S. smokers O...
-$0.64 per share
-$0.55 per share